Sionna Therapeutics Common Net Income
| SION Stock | 36.11 0.86 2.44% |
As of the 7th of February, Sionna Therapeutics has the Coefficient Of Variation of 3890.64, semi deviation of 5.36, and Risk Adjusted Performance of 0.0291. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sionna Therapeutics, as well as the relationship between them.
Sionna Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sionna Therapeutics' valuation are provided below:We have found ninety-seven available fundamental trend indicators for Sionna Therapeutics Common, which can be analyzed and compared to other ratios and to its competition. Self-guided Investors are advised to double-check Sionna Therapeutics' current fundamentals against the trend between 2010 and 2026 to make sure the company can sustain itself down the road. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. | Last Reported | Projected for Next Year | ||
| Net Loss | -55.5 M | -58.3 M | |
| Net Loss | -55.5 M | -58.3 M | |
| Net Loss | (1.61) | (1.69) |
Sionna | Net Income | Build AI portfolio with Sionna Stock |
Evaluating Sionna Therapeutics's Net Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Sionna Therapeutics Common's fundamental strength.
Latest Sionna Therapeutics' Net Income Growth Pattern
Below is the plot of the Net Income of Sionna Therapeutics Common over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in Sionna Therapeutics financial statement analysis. It represents the amount of money remaining after all of Sionna Therapeutics Common operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is Sionna Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sionna Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (61.69 M) | 10 Years Trend |
|
Net Income |
| Timeline |
Sionna Net Income Regression Statistics
| Arithmetic Mean | (43,875,609) | |
| Coefficient Of Variation | (16.55) | |
| Mean Deviation | 5,560,344 | |
| Median | (40,240,000) | |
| Standard Deviation | 7,263,272 | |
| Sample Variance | 52.8T | |
| Range | 21.4M | |
| R-Value | (0.71) | |
| Mean Square Error | 28.1T | |
| R-Squared | 0.50 | |
| Significance | 0 | |
| Slope | (1,017,644) | |
| Total Sum of Squares | 844.1T |
Sionna Net Income History
Other Fundumenentals of Sionna Therapeutics
Sionna Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Sionna Therapeutics is extremely important. It helps to project a fair market value of Sionna Stock properly, considering its historical fundamentals such as Net Income. Since Sionna Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Sionna Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Sionna Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.
Sionna Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sionna Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sionna Therapeutics.
| 11/09/2025 |
| 02/07/2026 |
If you would invest 0.00 in Sionna Therapeutics on November 9, 2025 and sell it all today you would earn a total of 0.00 from holding Sionna Therapeutics Common or generate 0.0% return on investment in Sionna Therapeutics over 90 days. Sionna Therapeutics is related to or competes with Janux Therapeutics, Abcellera Biologics, Maze Therapeutics, Biohaven Pharmaceutical, Celldex Therapeutics, Vera Therapeutics, and Xeris Pharmaceuticals. Sionna Therapeutics is entity of United States More
Sionna Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sionna Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sionna Therapeutics Common upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.66 | |||
| Information Ratio | 0.008 | |||
| Maximum Drawdown | 31.39 | |||
| Value At Risk | (8.89) | |||
| Potential Upside | 7.92 |
Sionna Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sionna Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sionna Therapeutics' standard deviation. In reality, there are many statistical measures that can use Sionna Therapeutics historical prices to predict the future Sionna Therapeutics' volatility.| Risk Adjusted Performance | 0.0291 | |||
| Jensen Alpha | 0.0985 | |||
| Total Risk Alpha | (0.38) | |||
| Sortino Ratio | 0.0072 | |||
| Treynor Ratio | 0.4373 |
Sionna Therapeutics February 7, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0291 | |||
| Market Risk Adjusted Performance | 0.4473 | |||
| Mean Deviation | 3.26 | |||
| Semi Deviation | 5.36 | |||
| Downside Deviation | 5.66 | |||
| Coefficient Of Variation | 3890.64 | |||
| Standard Deviation | 5.08 | |||
| Variance | 25.77 | |||
| Information Ratio | 0.008 | |||
| Jensen Alpha | 0.0985 | |||
| Total Risk Alpha | (0.38) | |||
| Sortino Ratio | 0.0072 | |||
| Treynor Ratio | 0.4373 | |||
| Maximum Drawdown | 31.39 | |||
| Value At Risk | (8.89) | |||
| Potential Upside | 7.92 | |||
| Downside Variance | 32.07 | |||
| Semi Variance | 28.73 | |||
| Expected Short fall | (3.04) | |||
| Skewness | (0.19) | |||
| Kurtosis | 3.09 |
Sionna Therapeutics Backtested Returns
As of now, Sionna Stock is not too volatile. Sionna Therapeutics owns Efficiency Ratio (i.e., Sharpe Ratio) of 0.0291, which indicates the firm had a 0.0291 % return per unit of risk over the last 3 months. We have found twenty-eight technical indicators for Sionna Therapeutics Common, which you can use to evaluate the volatility of the company. Please validate Sionna Therapeutics' Risk Adjusted Performance of 0.0291, semi deviation of 5.36, and Coefficient Of Variation of 3890.64 to confirm if the risk estimate we provide is consistent with the expected return of 0.15%. Sionna Therapeutics has a performance score of 2 on a scale of 0 to 100. The entity has a beta of 0.28, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sionna Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Sionna Therapeutics is expected to be smaller as well. Sionna Therapeutics right now has a risk of 5.26%. Please validate Sionna Therapeutics value at risk, as well as the relationship between the skewness and day median price , to decide if Sionna Therapeutics will be following its existing price patterns.
Auto-correlation | -0.32 |
Poor reverse predictability
Sionna Therapeutics Common has poor reverse predictability. Overlapping area represents the amount of predictability between Sionna Therapeutics time series from 9th of November 2025 to 24th of December 2025 and 24th of December 2025 to 7th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sionna Therapeutics price movement. The serial correlation of -0.32 indicates that nearly 32.0% of current Sionna Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.32 | |
| Spearman Rank Test | -0.05 | |
| Residual Average | 0.0 | |
| Price Variance | 6.74 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Sionna Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Sionna Therapeutics Common reported net income of (61.69 Million). This is 118.08% lower than that of the Biotechnology sector and 188.07% lower than that of the Health Care industry. The net income for all United States stocks is 110.8% higher than that of the company.
Sionna Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sionna Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Sionna Therapeutics could also be used in its relative valuation, which is a method of valuing Sionna Therapeutics by comparing valuation metrics of similar companies.Sionna Therapeutics is currently under evaluation in net income category among its peers.
Sionna Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Sionna Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Sionna Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Sionna Fundamentals
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.19 | ||||
| Current Valuation | 1.6 B | ||||
| Shares Outstanding | 44.63 M | ||||
| Shares Owned By Insiders | 6.92 % | ||||
| Shares Owned By Institutions | 94.03 % | ||||
| Number Of Shares Shorted | 3.05 M | ||||
| Price To Book | 5.73 X | ||||
| EBITDA | (69.89 M) | ||||
| Net Income | (61.69 M) | ||||
| Total Debt | 9.75 M | ||||
| Book Value Per Share | 7.23 X | ||||
| Cash Flow From Operations | (52.79 M) | ||||
| Short Ratio | 8.65 X | ||||
| Earnings Per Share | (1.80) X | ||||
| Target Price | 44.86 | ||||
| Number Of Employees | 41 | ||||
| Market Capitalization | 1.57 B | ||||
| Total Asset | 185.75 M | ||||
| Retained Earnings | (181.09 M) | ||||
| Working Capital | 140.57 M | ||||
| Net Asset | 185.75 M |
About Sionna Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sionna Therapeutics Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sionna Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sionna Therapeutics Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Sionna Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Sionna Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sionna Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Sionna Stock
Moving against Sionna Stock
| 0.58 | KRRO | Frequency Therapeutics | PairCorr |
| 0.57 | EVGN | Evogene | PairCorr |
| 0.44 | JUMP | Leveljump Healthcare Corp | PairCorr |
| 0.44 | QSI | QuantumSi | PairCorr |
| 0.33 | IMRN | Immuron Ltd ADR | PairCorr |
The ability to find closely correlated positions to Sionna Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Sionna Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Sionna Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Sionna Therapeutics Common to buy it.
The correlation of Sionna Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Sionna Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Sionna Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Sionna Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Will Biotechnology sector continue expanding? Could Sionna diversify its offerings? Factors like these will boost the valuation of Sionna Therapeutics. If investors know Sionna will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sionna Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Investors evaluate Sionna Therapeutics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Sionna Therapeutics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Sionna Therapeutics' market price to deviate significantly from intrinsic value.
Please note, there is a significant difference between Sionna Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sionna Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Sionna Therapeutics' market price signifies the transaction level at which participants voluntarily complete trades.